In primary hyperparathyroidism, one or more of the parathyroid glands produces too much of a hormone that regulates blood calcium levels. If the imbalance becomes serious enough, it can lead to bone or kidney disease and require removal of the gland.
The federal government’s dietary guidelines are likely to Include recommendations to reduce sodium intake, take vitamin D, avoid solid fats, and more.
A five-year study funded by the National Institutes of Health hopes to determine whether vitamin D and omega-3 fats have an effect on rates of cardiovascular disease or cancer.
Colon cancer is highly preventable, and many factors influence a person’s risk. Diet and exercise, unsurprisingly, factor heavily.
In a small study of leg fractures, nearly all of the people with an unusual type of fracture were taking bone-building drugs. The drugs are called bisphosphonates. They include alendronate (Fosamax), risedronate (Actonel) and ibandronate (Boniva). The drugs are prescribed for people with osteoporosis. In general, they help to strengthen bones and prevent fractures. But recently, doctors have noticed that some people taking them have an unusual type of fracture of the thigh bone (femur). The new study looked at 152 femur fractures. Of these, 20 were the unusual type. And 17 of the 20 people with these fractures had been taking bisphosphonates. People with these fractures also were more likely than others to have rheumatoid arthritis. Many also had taken steroid medicines for at least six months.
A new drug improves treatment response for people with hepatitis C, two studies show. One study included 1,097 people who had not been treated for hepatitis C before. They had genotype 1, which is hard to treat. Two groups of patients were given boceprevir, a new drug. They took it for either 24 or 44 weeks. The third group received a placebo (fake pills) instead. All 3 groups also got standard drugs for the whole study period and 4 weeks before it began. Researchers looked at how many people had a sustained biologic response. This means they had no genetic material (RNA) from hepatitis C in their blood 24 weeks after treatment ended. Blacks and non-blacks responded differently. About 68% of non-blacks taking boceprevir had a sustained response. The rate was 40% for those who got the placebo.